Telisotuzumab Vedotin
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications
Targeting MET in 2025: From Exon 14 Skipping to MET-Amplified Acquired Resistance in Non-Small Cell Lung Cancer.
Journal: International journal of molecular sciences
Published: May 01, 2026
An evaluation of telisotuzumab vedotin for the treatment of non-squamous non-small cell lung cancer.
An evaluation of telisotuzumab vedotin for the treatment of non-squamous non-small cell lung cancer.
Journal: Expert opinion on biological therapy
Published: April 29, 2026
Neurotrophic Keratitis Associated With Telisotuzumab Vedotin: A Case Report.
Journal: Cornea
Published: April 13, 2026
MET Expression in Upper Gastrointestinal Adenocarcinoma: Prevalence, Prognostic Impact, and Implications for Anti-MET Antibody-Drug Conjugate Therapy.
Journal: International journal of cancer
Published: March 12, 2026
Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation.
Journal: ESMO open
Published: March 10, 2026
Population Pharmacokinetics and Exposure-Response Analyses for Telisotuzumab Vedotin in Patients With c-Met Protein Overexpressing Tumors.
Journal: CPT: pharmacometrics & systems pharmacology
Published: January 29, 2026
Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer.
Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: January 17, 2026
Emrelis: A New Approach in Treating MET-high Locally Advanced or Metastatic Non-squamous NSCLC; A Mini Review.
Journal: Thoracic research and practice
Published: December 29, 2025
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial.
Journal: JTO clinical and research reports
Published: October 21, 2025
Emrelis for c-Met Positive NSCLC: A Breakthrough in Antibody-Drug Conjugate-based Treatment Approved by the FDA.
Journal: Anti-cancer agents in medicinal chemistry
Published: September 11, 2025
An overview of recent advancements in targeted cancer therapies and their potential clinical impact.
An overview of recent advancements in targeted cancer therapies and their potential clinical impact.
Journal: RSC medicinal chemistry
Published: August 23, 2025
Last Updated: 09/26/2026